• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> methods for determining the appropriateness of anticancer therapy, composition, kit and method for enhancing the treatment effect of a chemotherapy regimen

methods for determining the appropriateness of anticancer therapy, composition, kit and method for enhancing the treatment effect of a chemotherapy regimen

机译：确定合适的抗癌方法的方法，组合物，试剂盒和增强化疗方案治疗效果的方法

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
机译：本发明提供了通过确定贝伐单抗的表达，将贝伐单抗（Avastin？）添加到化疗方案中来改善患有HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的化疗方案的治疗效果的方法。相对于诊断出患有HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的对照水平，VEGFA和/或VEGFR2的水平，特别是血浆表达水平。本发明还提供了通过确定VEGFA和/或VEGFR2相对蛋白的表达水平，特别是血浆表达水平，结合化疗方案评估患者对贝伐单抗（Avastin？）的敏感性或反应性的方法。以控制诊断为HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的水平。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号